Biotechnology Industry Organization

Based in DC

🤖

AI Overview

With $2.6M in lobbying spend across 33 quarterly filings, Biotechnology Industry Organization is a significant lobbying presence. They deploy 12 individual lobbyists

$2.6M
Total Lobbying Spend
33
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$240K
2019$320K
2020$240K
2021$400K
2022$400K
2023$400K
2024$320K
2025$320K

Lobbying Firms

TARPLIN, DOWNS & YOUNG, LLC

What They Lobby For

  • PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation
  • Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, donut hole, Part D cliff, prescription drug access and affordability S. 870 - Chronic Care H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017 S. 260/H.R. 849 - Protecting Seniors' Access to Medicare Act of 2017
  • pharmaceutical tax, orphan drug tax credit
  • PL 114-255 - 21st Century Cures, implementation S. 456 - RACE for Children Act S. 771 - Improving Access to Affordable Prescription Drugs Act S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017 S. 469 - Affordable and Safe Prescription Drug Importation act H.R. 749 - Lower Drug Costs Through Competition Act H.R. 878/S. 204 - Right to Try Act of 2017 H.R. 1480/S. 64/S. 92 - Safe and Affordable Drugs from Canada Act of 2017 H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 6 - SUPPORT for Patients and Communities Act S. 3120 - HEAL Substance Use Disorders Act S. 2680 - Opioid Crisis Response Act S. 2852 - Pandemic and All Hazards Preparedness Act ***, no specific bill(s), health care reform, Biosimilars, PDUFA and related FDA policies, Innovation, 340B, comparative effectiveness research, user fee reauthorization, non-interference, IPAB
  • budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 2019 Appropriations
  • budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution
  • budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution H.R. 695 - Department of Defense Appropriations Act
  • Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, prescription drug access and affordability, transparency H.R. 1839 - Medicaid Services Investment and Accountability Act of 2019
  • budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.J.Res. 31 - Consolidated Appropriations Act, 2019
  • H.R. 1781 - Payment Commission Data Act of 2019 H.R. 938 - the BLOCKING Act of 2019 H.R. 1520 - the Purple Book Continuity Act of 2019 H.R. 1503 - the Orange Book Transparency Act of 2019 H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 H.R. 965 - the CREATES Act of 2019 no specific bills, health care reform, Biosimilars, PDUFA and related FDA policies, Innovation, 340B, comparative effectiveness research, user fee authorization, non-interference, opioids

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.